Literature DB >> 22496119

Attention skills in children with neurofibromatosis type 1.

Jill C Isenberg1, Alexandra Templer, Feng Gao, Jeffrey B Titus, David H Gutmann.   

Abstract

Children with neurofibromatosis type 1 are at increased risk for the development of attention problems relative to their unaffected peers. Previous studies have reported deficits in sustained auditory attention, but other aspects of attention, including sustained visual attention, divided attention, response inhibition, and selective attention, have not been consistently documented. In the present study, we specifically investigated attention skills in children with neurofibromatosis type 1 using measures of visual and sustained auditory attention, divided attention, selective attention, and response inhibition. Consistent with previous reports, we confirmed the presence of deficits in sustained visual and auditory attention in children with neurofibromatosis type 1 but also identified deficits in divided attention and response inhibition. Based on the high frequency and wide spectrum of attention system impairments in this at-risk population, we advocate screening children with neurofibromatosis type 1 for attention problems and providing appropriate interventions that address all aspects of their executive functioning.

Entities:  

Mesh:

Year:  2012        PMID: 22496119     DOI: 10.1177/0883073812439435

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  20 in total

1.  Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.

Authors:  Corina Anastasaki; Albert S Woo; Ludwine M Messiaen; David H Gutmann
Journal:  Hum Mol Genet       Date:  2015-03-18       Impact factor: 6.150

Review 2.  Neurofibromatosis type 1: modeling CNS dysfunction.

Authors:  David H Gutmann; Luis F Parada; Alcino J Silva; Nancy Ratner
Journal:  J Neurosci       Date:  2012-10-10       Impact factor: 6.167

3.  Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.

Authors:  Joseph A Toonen; Yu Ma; David H Gutmann
Journal:  Neuro Oncol       Date:  2017-06-01       Impact factor: 12.300

4.  Longitudinal Investigation of Early Motor Development in Neurofibromatosis Type 1.

Authors:  Sara K Pardej; Danielle M Glad; Christina L Casnar; Kelly M Janke; Bonita P Klein-Tasman
Journal:  J Pediatr Psychol       Date:  2022-02-14

5.  Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.

Authors:  Karin S Walsh; Jennifer Janusz; Pamela L Wolters; Staci Martin; Bonita P Klein-Tasman; Mary Anne Toledo-Tamula; Heather L Thompson; Jonathan M Payne; Kristina K Hardy; Peter de Blank; Claire Semerjian; Laura Schaffner Gray; Sondra E Solomon; Nicole Ullrich
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

Review 6.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

7.  Prevalence of Sleep Disturbances in Children With Neurofibromatosis Type 1.

Authors:  Amy K Licis; Alicia Vallorani; Feng Gao; Cynthia Chen; Jason Lenox; Kelvin A Yamada; Stephen P Duntley; David H Gutmann
Journal:  J Child Neurol       Date:  2013-09-23       Impact factor: 1.987

8.  The impact of coexisting genetic mutations on murine optic glioma biology.

Authors:  Aparna Kaul; Joseph A Toonen; Scott M Gianino; David H Gutmann
Journal:  Neuro Oncol       Date:  2014-09-21       Impact factor: 12.300

9.  Neurofibromatosis type 1 and attention deficit hyperactivity disorder: a case study and literature review.

Authors:  Carmen Sílvia Miguel; Tiffany M Chaim-Avancini; Maria Aparecida Silva; Mario Rodrigues Louzã
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-25       Impact factor: 2.570

Review 10.  Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1.

Authors:  Martha Milade Torres Nupan; Alberto Velez Van Meerbeke; Claudia Alejandra López Cabra; Paula Marcela Herrera Gomez
Journal:  Front Pediatr       Date:  2017-10-30       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.